Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00834665 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT00834665: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT00834665 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 59 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00834665, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is: 1. To evaluate the safety of activated T cell infusions and immunization with hTERT multi-peptide vaccine in the post-transplant setting and whether the combination can delay hematopoietic recovery or induce other autoimmune events. 2. To determine whether the strategy of infusing vaccine-primed T-cells early after transplant in conjunction with post-transplant boosters leads to the induction of cellular immune responses to hTERT.
Primary Outcome
Incidence of delayed hematopoietic recovery and the incidence of Grade 3 or greater autoimmune events
Interventions
- BIOLOGICAL hTERT vaccine, GM-CSF, PCV, T cell infusion
- BIOLOGICAL GM-CSF, PCV, T cell infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2006-12 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
What the finished NCT00834665 record still lists
NCT00834665 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which hTERT vaccine, GM-CSF, PCV, T cell infusion is the first listed.
NCT00834665 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00834665 about?
NCT00834665 is a clinical study titled "Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma". The purpose of this study is: 1. To evaluate the safety of activated T cell infusions and immunization with hTERT multi-peptide vaccine in the post-transplant setting and whether the combination can delay hematopoietic recovery or induce other autoimmune events. 2. To determine whether the strategy...
What is the current status of trial NCT00834665?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2006-12. Estimated completion is 2017-12.
What interventions are being tested in trial NCT00834665?
The interventions under investigation include: hTERT vaccine, GM-CSF, PCV, T cell infusion (BIOLOGICAL), GM-CSF, PCV, T cell infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT00834665?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00834665's enrollment target sits among peer trials
59 895th of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia